Following layoff reports, Exact Sciences announces Q3 revenue up

Exact Sciences Corp. announced that it generated revenue of $523 million for the third quarter that ended Sept. 30, compared to $456 million for the same period in 2021. Full-year revenue for the cancer screening and diagnostic test company grew by $33 million and operating expenses decreased by $113 million. Screening revenue for products like Cologuard was $360.8 million, an increase of 29%. Adjusted EBITDA profitability is now expected in the third quarter of 2023 rather than the previous target of 2024.